Organoids: A Platform Ready for Glioblastoma Precision Medicine?

Wei-Lin Jin¹, Ming-Zhu Jin², Yan-Yang Tu³

Affiliations

¹ Center for Translational Medicine, Affiliated Hospital of Guilin Medical University, Guilin 541004, China; Institute of Nano-Biomedicine and Engineering, Department of Instrument Science and Engineering, School of Electronic Information and Electronic Engineering, Shanghai Jiao Tong University, Shanghai 200240, China. Electronic address: weilinjin@sjtu.edu.cn.
² Department of Gynecology and Obstetrics, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.
³ Center for Translational Medicine, Affiliated Hospital of Guilin Medical University, Guilin 541004, China.

PMID: 32209439
DOI: 10.1016/j.trecan.2020.01.016

Comment

Organoids: A Platform Ready for Glioblastoma Precision Medicine?

Wei-Lin Jin et al. Trends Cancer. 2020 Apr.

. 2020 Apr;6(4):265-267.

doi: 10.1016/j.trecan.2020.01.016. Epub 2020 Feb 6.

Authors

Wei-Lin Jin¹, Ming-Zhu Jin², Yan-Yang Tu³

Affiliations

¹ Center for Translational Medicine, Affiliated Hospital of Guilin Medical University, Guilin 541004, China; Institute of Nano-Biomedicine and Engineering, Department of Instrument Science and Engineering, School of Electronic Information and Electronic Engineering, Shanghai Jiao Tong University, Shanghai 200240, China. Electronic address: weilinjin@sjtu.edu.cn.
² Department of Gynecology and Obstetrics, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.
³ Center for Translational Medicine, Affiliated Hospital of Guilin Medical University, Guilin 541004, China.

PMID: 32209439
DOI: 10.1016/j.trecan.2020.01.016

Abstract

Patient-derived organoids can recapitulate parental tumor heterogeneity. In a recent study in Cell, Jacob et al. cultivated glioblastoma organoids (GBOs) to mimic tumor heterogeneity and chimeric antigen receptor (CAR)-T cell immunotherapy, applied it for xenograft establishment and drug testing, and generated a biobank for the timely start of post-operation therapy.

PubMed Disclaimer

Comment on

A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity.
Jacob F, Salinas RD, Zhang DY, Nguyen PTT, Schnoll JG, Wong SZH, Thokala R, Sheikh S, Saxena D, Prokop S, Liu DA, Qian X, Petrov D, Lucas T, Chen HI, Dorsey JF, Christian KM, Binder ZA, Nasrallah M, Brem S, O'Rourke DM, Ming GL, Song H. Jacob F, et al. Cell. 2020 Jan 9;180(1):188-204.e22. doi: 10.1016/j.cell.2019.11.036. Epub 2019 Dec 26. Cell. 2020. PMID: 31883794 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Organoids: A Platform Ready for Glioblastoma Precision Medicine?

Affiliations

Organoids: A Platform Ready for Glioblastoma Precision Medicine?

Authors

Affiliations

Abstract

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources